Archive | NAIT RSS for this section

New Agent and Innovative Therapies Program (NAIT) June newsletter available now

Download the newsletter here: https://mcusercontent.com/0a22c0fb4750c9511cde46055/files/ef7b4e00-6228-4efb-af43-f1228300a0ef/NAIT_newsletter_June_2020.pdf

UPDATES

  • Slots are now available on the solid tumour cohort (and ALL, NHL) for venetoclax (with cyclo/topotecan)
  • OZM-077 (carboplatin/azacitidine) study has now been amended to permit enrolment of patients with CNS or solid tumours other than ependymoma in expansion phase
  • RET inhibitor study is now open
  • New neuroblastoma study (aurora kinase inhibitor) is now open

Please note that despite COVID-19 restrictions, all NAIT studies continue to be open to enrollment

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at  http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) February newsletter available now

Download the newsletter here: https://mcusercontent.com/0a22c0fb4750c9511cde46055/files/d5debdb1-7646-470f-af1a-50bc08338230/NAIT_newsletter_February_2020.pdf

UPDATES

  • Slots are now available on the NANT study of lorlatinib (ALK inhibitor) for patients with neuroblastoma with ALK aberrations
  • Slots are available on the solid tumour cohort (and All, NHL) for venetoclax (with cyclo/topotecan)
  • A new study of targeted radiotherapy for patients with relapsed solid tumour, lymphoma or malignant brain tumours is now open (DCL-17-001). This study uses phospholipid ethers to target radiation to tumour cells. Limited slot availability – please contact us for waitlist information. Patients at higher dose levels will require available PBSCs.
  • Avelumab study has completed Phase I and awaiting details about dose expansion cohorts for Phase II.
  • ADVL1412 is currently closed to enrolment pending review of toxicities
  • Afatinib study is currently closed to enrolment

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at  http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) December newsletter available now

Download the newsletter here: https://gallery.mailchimp.com/0a22c0fb4750c9511cde46055/files/72df2e59-b775-4858-b2fc-1aa468ebc9a0/NAIT_newsletter_December_2019.pdf

UPDATES

  • A new study of targeted radiotherapy for patients with relapsed solid tumour, lymphoma or malignant brain tumours is now open (DCL-17-001). This study uses phospholipid ethers to target radiation to tumour cells. Limited slot availability – please contact us for waitlist information. Patients at higher dose levels will require available PBSCs.
  • Venetoclax study now likely to have completed enrolment for AML cohort; remains open for ALL, NHL and solid tumours. Venetoclax (Bcl-2 inhibitor) is given in combination with chemotherapy.
  • Avelumab study has completed Phase I and awaiting details about dose expansion cohorts for Phase II.
  • OZM-077 (vidaza/carboplatin) study has completed dose escalation and is now open only for patients with ependymoma.
  • NANT 2011-01 (MIBG study) has completed enrolment. MIBG therapy remains available outside this trial.

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at  http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) October newsletter available now

Download the newsletter here: https://gallery.mailchimp.com/0a22c0fb4750c9511cde46055/files/b29d02a7-b710-4dba-a1d4-e07a75d3d609/NAIT_newsletter_October_2019.pdf

UPDATES
  • ADVL1412 (nivolumab/ipilimumab) has now reopened for patients with Ewing sarcoma and rhabdomyosarcoma. Patients should have available archival tissue but are not required to demonstrate PDL1 expression for enrolment.
  • Venetoclax study has now reopen at SickKids for patients with solid tumours
  • ymAbs201 (hu3F8) – we have treated the first patient in Canada on this protocol – for consolidation of response in primary or secondary refractory/residual disease in HR neuroblastoma

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) September newsletter available now

UPDATES:

  • ADVL1412 (nivolumab/ipilimumab) is being amended to reopen for patients with Ewing sarcoma and rhabdomyosarcoma. Patients should have available archival tissue but are not required to demonstrate PDL1 expression for enrollment.

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) August newsletter available now

UPDATES:

  • ADVL1412 (nivolumab/ipilimumab) is being amended to reopen for patients with Ewing sarcoma and rhabdomyosarcoma. Awaiting REB approval.
  • Tazemetostat Phase I study – Cohort for patients with ATRT is now closed

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) Newsletter Early phase trials at SickKids

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Additional contacts:
  • Solid tumour: Dr Daniel Morgenstern daniel.morgenstern@sickkids.ca
  • CNS: Dr Eric Bouffet eric.bouffet@sickkids.ca
  • Leukaemia/lymphoma: Dr Jim Whitlock jim.whitlock@sickkids.ca
  • Patient Navigator: Karen Fung karen.fung@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

Now open at Sick Kids: NANT 2015-02 Phase I study of LORLATINIB and LOXO-TRK-15003 Phase I/II study of LAROTRECTINIB

NANT 2015-02 Phase I study of LORLATINIB (ALK inhibitor)

  • Relapsed/refractory neuroblastoma only
  • Need confirmed ALK activating mutation or ALK amplification*
  • Need evaluable or measurable disease
  • Oral medication
  • Academic study, therefore no funding for patient travel/accommodation

* ALK testing is not available as part of the study, but please contact us since we have the assay available at SickKids


LOXO-TRK-15003 Phase I/II study of LAROTRECTINIB (LOXO-101, NTRK inhibitor)

  • Relapsed/refractory solid tumour or CNS tumour, particularly relevant for infantile fibrosarcoma
  • Need a documented NTRK fusion
  • Need evaluable or measurable disease
  • Oral medication
  • Pharma company funding is available to assist with patient travel/accommodation

NAIT August Newsletter Available Now – CTL019 now open

CTL019 CAR-T study now open at Sick Kids: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients   see: https://clinicaltrials.gov/ct2/show/NCT02228096

The August 2017 NAIT newsletter can be found HERE.

For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

NEW AGENTS & INNOVATIVE THERAPY PROGRAM – July newsletter available

TACL 2014-001 now open at Sick Kids (also open at Ste-Justine and BC Children’s):  A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma.  For more information see: https://clinicaltrials.gov/ct2/show/NCT01614197

 

The July 2017 NAIT newsletter can be found HERE..

For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.